Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.47 |
| ▸ | WNT3A | P56704 | 2/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 5/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4772656 | 0.98 | P2RX7 (0.55) | P2RX7FAAHCTNNB1WNT3AGRM4 | |
| SCHEMBL882670 | 0.80 | P2RX7 (0.56) | P2RX7FAAHCTNNB1WNT3AGRM4 | |
| SCHEMBL30481578 | 0.80 | P2RX7 (0.56) | P2RX7FAAHCTNNB1WNT3AGRM4 | |
| SCHEMBL2293958 | 0.78 | P2RX7 (0.59) | P2RX7FAAHCTNNB1WNT3AGRM4 | |
| Bromide SCHEMBL28037038 | 0.78 | P2RX7 (0.55) | P2RX7FAAHCTNNB1WNT3AGRM4 | |
| SCHEMBL5160553 | 0.77 | P2RX7 (0.68) | P2RX7FAAHCTNNB1WNT3AGRM4 | |
| SCHEMBL4363009 | 0.77 | P2RX7 (0.53) | P2RX7FAAHCTNNB1WNT3AGRM4 | |
| SCHEMBL12208551 | 0.77 | P2RX7 (0.58) | P2RX7FAAHCTNNB1WNT3AGRM4 | |
| SCHEMBL18906056 | 0.77 | CTNNB1 (0.55) | P2RX7FAAHCTNNB1WNT3AGRM4 | |
| SCHEMBL11563546 | 0.77 | FAAH (0.64) | P2RX7FAAHCTNNB1WNT3AGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| CN-116981667-A | Heterocyclic inhibitors of EGFR and/or HER2 for cancer treatment | 蝎子疗法股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4225445-A2 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076831-A2 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3290413-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-20170305917-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9732085-B2 | Pyridinone and pyrimidinone derivatives as factor Xia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-9056854-B2 | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-06-16 | — | — | US | disclosed |
| US-20150152112-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150051237-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-19 | — | — | US | disclosed |
| US-8906934-B2 | Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene-and furane-derivatives as kinase inhibitors | Nerviano Medical Science S.R.L. (IT) | 2014-12-09 | — | — | US | disclosed |
| EP-2004623-B1 | PYRIDYL- AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-10-09 | — | — | EP | disclosed |
| US-20120295906-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-22 | — | — | US | disclosed |
| US-8263604-B2 | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-09-11 | — | — | US | disclosed |
| US-20090099221-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-04-16 | — | — | US | disclosed |
| EP-2004623-A1 | PYRIDYL- AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007110344-A1 | PYRIDYL- AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051237-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK1, CDK5 | P2RX7 969/4885FAAH 4582/4885CTNNB1 2656/4885 |
| US-20090099221-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK1, CDK5 | P2RX7 1004/4885FAAH 4605/4885CTNNB1 2651/4885 |
| US-20150152112-A1 | COMPOUNDS | F11, F12, F10 | P2RX7 2105/4885FAAH 1857/4885CTNNB1 1551/4885 |
| US-20120295906-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK1, CDK5 | P2RX7 969/4885FAAH 4582/4885CTNNB1 2656/4885 |
| US-20170305917-A1 | COMPOUNDS | F11, F12, F10 | P2RX7 2105/4885FAAH 1857/4885CTNNB1 1551/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | P2RX7 1119/4885FAAH 3423/4885CTNNB1 2133/4885 |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | P2RX7 1715/4885FAAH 1304/4885CTNNB1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.